Live

China retaliated to President Trump's tariffs with 34% duties on US goods. See the latest.

NasdaqGM - Delayed Quote USD

Astria Therapeutics, Inc. (ATXS)

5.15

-0.37

(-6.70%)

At close: April 3 at 4:00:02 PM EDT

5.02

-0.13

(-2.52%)

Pre-Market: 7:01:07 AM EDT

No Tool

Measure

UNDO

Redo

All

All

Favorites

Text

Statistics

Technicals

Fibonacci

Markings

Lines

Annotation

Arrow

Line

Horizontal

Vertical

Rectangle

Trend Line

Measurement Line

Average Line

Callout

Channel

Check

Continuous

Crossline

Elliott Wave

Ellipse

Doodle

Fib Projection

Fib Arc

Fib Fan

Fib Time Zone

Focus

Gann Fan

Gartley

Heart

Pitchfork

Quadrant Lines

Ray

Regression Line

Fib Retracement

Star

Speed Resistance Arc

Speed Resistance Line

Time Cycle

Tirone Levels

Volume Profile

Cross

Loading Chart for ATXS

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema

Astria Therapeutics Initiates ALPHA-ORBIT Phase 3 Pivotal Trial of Navenibart in Hereditary Angioedema

Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference

Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference

Calculating The Intrinsic Value Of Astria Therapeutics, Inc. (NASDAQ:ATXS)

Calculating The Intrinsic Value Of Astria Therapeutics, Inc. (NASDAQ:ATXS)

Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress

Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma and Immunology and World Allergy Organization Joint Congress

Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference

Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference

Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session

Astria Therapeutics to Present at Upcoming Western Society of Allergy, Asthma & Immunology Annual Scientific Session

Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE

Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE

Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE

Astria Therapeutics Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE

PMVP PMV Pharmaceuticals, Inc.

0.9950

-0.50%

RAPT RAPT Therapeutics, Inc.

1.1100

-4.31%

SYRE Spyre Therapeutics, Inc.

13.99

-9.68%

AVTE Aerovate Therapeutics, Inc.

2.5100

-0.40%

ORKA Oruka Therapeutics, Inc.

8.92

-5.31%

GHRS GH Research PLC

9.86

-5.19%

ENGN enGene Holdings Inc.

4.5000

+1.35%

CGEM Cullinan Therapeutics, Inc.

7.49

-4.22%

ARTV Artiva Biotherapeutics, Inc.

2.5400

-11.19%

ANTX AN2 Therapeutics, Inc.

1.4000

0.00%

Try again.